NCT00070616View on ClinicalTrials.gov

Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
LeukemiaLymphomaMyeloma
Interventions
DRUG

Palifermin 6 x 60 μg/kg/day

DRUG

Palifermin 2 x 180 μg/kg/day

RADIATION

radiotherapy

DRUG

Chemotherapy

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Swedish Orphan Biovitrum

INDUSTRY